

Experts from around the World to Speak at United Scientific Group's Cancer Research and Targeted Therapy Conference

The Third International Conference on Cancer Research and Targeted Therapy is Scheduled during August 6-8, 2018 at London, England

PLANO, TEXAS, UNITED STATES, March 6, 2018 /EINPresswire.com/ -- The third International Conference on [Cancer](#) Research and Targeted Therapy is scheduled during August 6-8, 2018 at Renaissance [London](#) Heathrow Hotel, London, UK ([CRT-2018](#)).

With an expected rise of the number of new cases of cancer by about 70% over the next 2 decades, there is a much more research is desperately needed in oncology.

With the accomplishments and the support from the previous two editions in United States at Baltimore, MD (2016) and Miami, FL (2017), CRT-2018 London is gearing up to make the stage more steering and motivating; covering a broad selection of subjects including basic science, clinical research, therapy and prevention.

CRT-2018 will witness experts from more than 15 countries to speak and discuss the advancements and information about clinical studies and latest research in the field of cancer science.

Speakers at CRT-2018:

Andrew V. Schally, Nobel Laureate 1977, University of Miami, FL, USA
Graham Pawelec, University of Tuebingen Center for Medical Research (ZMF), Germany
Olivier E Pardo, Imperial College, London, UK
Olivier Dormond, CHUV, Switzerland
Myron R Szewczuk, Queen's University, Kingston, Canada
Indraneel Mitra, Tata Memorial Centre, MH, India

As cancer treatment is currently focused mainly on cancer immunotherapy, a symposium entitled "Immunotherapy of Cancer: Triumphs and Challenges" is scheduled and which will be chaired by Dr. Graham Pawelec, Professor of Experimental Immunology, Second Department of Internal Medicine, University of Tuebingen Center for Medical Research (ZMF), Germany. Other speakers of this symposium include:



Nobel Laureate Prof Andrew V. Schally speaking at CRT Miami, FL, October 26, 2017



CRT-2018

International Conference on Cancer Research and Targeted Therapy, London, England, August 2018

Dr. Thomas Sayers, NIH/NCI Frederick, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, USA

Dr. Marek K. Janiak, Military Institute of Hygiene and Epidemiology, Poland, and

Dr. Serge Y. Fuchs, Department of Biomedical Sciences, University of Pennsylvania, PA, USA.

The essence of CRT-2018 is that the experts will present and openly discuss projects at the forefront of their field, their prospective on early diagnosis and more effective treatments and therapies; one step closer.

CRT also provides a platform for young scientists from across the world to share their discoveries and forge new concepts in cancer science research and to stimulate progression in this important research area across the globe.

Abstract submission is open and group discounts on registration are available. Further information and regular updates on the website: visit <https://unitedscientificgroup.com/conferences/cancer-research-therapy/>

About Organizers:

United Scientific Group (USG), an expert-driven initiative led by the editor's association and the advisory board which includes academicians, researchers, and industry leaders across various fields of research. USG provides broad range of services in the fields of science and technology including publishing, conducting world class scientific events, and holding highly interactive and proficient world forums. For more information visit: <http://unitedscientificgroup.com/>.

Dr. Kenneth Blum, Dr. Venkata Dasari & Ms. Kinnera Kalagara

United Scientific Group, LLC

4084264833

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.